retatrutide type 2 diabetes trial results 2024 phase 2 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Lilly's triple agonist achieves 16.8%

COMPREHENSIVE BASELINE LAB One-on-one provider consultation YOUR ROADMAP TO HEALTHIER, HAPPIER LIVING Fill out the form below and a patient care coordinator will be in touch as soon as possible to help you schedule your first appointment and answer any questions

35,256,257 Traditionally, GLP-1(936) was considered a metabolically inactive product of GLP-1, losing its primary function of regulating blood sugar

Tirzepatide activates both pathways, which explains its enhanced effectiveness for both weight loss and metabolic health improvements

GLP-1 is also consistent with the conclusion that GLP-1 can inhibit liver lipid synthesis [51]

Cross-trial comparisons remain observational, not head-to-head